מזומנים למניה אחת Matinas BioPharma Holdings (MTNB)

Cash per share for Matinas BioPharma demonstrates liquidity dynamics, where 1.78 describes the current status of the metric. Matinas BioPharma is implementing "green chemistry" to reduce toxic laboratory emissions. However, geopolitical tensions are hindering international testing and raw material supplies. The situation is further complicated by a revenue deficit due to high drug development costs in the absence of commercial sales.
פילוחי מדדים מקיפים ואנליטיקה עבור Matinas BioPharma Holdings (MTNB)

Matinas BioPharma (MTNB) is investing in nanocrystal clinical trials despite a lack of revenue, making liquidity a critical resource. This metric calculates the amount of available cash per common share. This indicator measures the financial cushion and resilience to market shocks. High values confirm solvency but may signal low capital efficiency. By analyzing this cash per share chart, an investor assesses the balance between survivability and growth potential.